UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-42875 Turn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q Delaware 32-0456090 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 (State ...

Exhibit 99.1 Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer and distributor Medline Los Angeles, CA — November 13, 2025 — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today reported financial results for the third quarter ended September 30, ...

Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer and distributor Medline LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, t ...

Company Overview - Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for dermatology, advanced wound care, and infectious diseases [3] - The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [3] - Turn Therapeutics is also engaged in global health initiatives, particularly in thermostable vaccine delivery aimed at underserved areas worldwide [3] Leadership and Public Engagement - CEO Brad Burnam emphasized the importance of restoring public trust in health authorities during a conversation with Dr. Robert Redfield, former CDC Director [2] - The discussion highlighted the obligation of companies and public health authorities to communicate fact-based science to the public [2] - Dr. Redfield is recognized for his advocacy of science-based decision-making and has made significant contributions to HIV research [2]

Core Insights - Turn Therapeutics Inc. has been recognized as one of the "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine, highlighting its innovative approach in the dermatology sector [1][2] Company Overview - Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases [3] - The company has received three FDA clearances for its proprietary formulations in wound and dermatology care and is advancing late-stage clinical programs in eczema and onychomycosis [3] - Turn is also engaged in global health initiatives, particularly in thermostable vaccine delivery aimed at underserved areas, reflecting its commitment to public health innovation [3] Product Development - The company's GX-03 technology targets IL-36, which is involved in the inflammatory processes of atopic dermatitis, eczema, and psoriasis, representing a novel topical agent that offers an alternative to systemic and injectable treatments [2] - Studies have shown that GX-03 can inhibit several key targets, including IL-36 alpha, IL-31, IL-4, and IL-36 gamma, all associated with eczema and psoriasis [2] - Turn Therapeutics is expected to announce topline data from its lead program in severe eczema in early 2026 [2]

Core Insights - Turn Therapeutics Inc. has appointed Andrew Scott as Vice President of Corporate Communications to enhance investor relations and capital markets strategy as the company enters a new growth phase following its public listing [2][3] Company Overview - Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases [3] - The company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis [3] - Turn Therapeutics is also pursuing global health initiatives in thermostable vaccine delivery aimed at underserved areas worldwide, reflecting its commitment to public health innovation [3] Leadership Background - Andrew Scott brings over 30 years of experience in capital markets and corporate finance, having previously served as Managing Director of Investment Banking at ThinkEquity LLC and Vice President of Business Development at Fortress Biosciences, Inc. [2] - Throughout his career, Mr. Scott has helped raise approximately $3 billion across various transactions within the life sciences sector [2]

Core Insights - Turn Therapeutics has entered into a global supply, development, and license agreement with Medline, enhancing its capabilities in dermatology, wound care, and anti-infective therapies [1][2][3] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases, with three FDA clearances for its proprietary formulations [5] - The company is advancing late-stage clinical programs in eczema and onychomycosis and is also involved in global health initiatives for thermostable vaccine delivery [5] Partnership Details - The collaboration with Medline aims to leverage Turn's proprietary PermaFusion® delivery platform for product development, manufacturing, and commercialization [2][3] - Medline is recognized as the largest provider of medical-surgical products and supply chain solutions, operating in over 100 countries and employing more than 43,000 people [4] Strategic Implications - The partnership is viewed as a transformative milestone for Turn, allowing the company to focus on scientific innovation while utilizing Medline's extensive infrastructure to reach professional and consumer markets [3]

Core Insights - Turn Therapeutics is making significant progress in its clinical programs while maintaining a flexible financing strategy through a dilution-sparing direct listing [1][2][3] Capital Strategy and Alignment - The company opted for a direct listing to enhance flexibility and align with long-term shareholder interests, allowing early shareholders to retain their ownership [2] - Through an $85 million GEM Global Yield agreement, Turn has established a flexible financing mechanism that enables opportunistic capital access without the need for traditional offerings at the time of listing [3] Pipeline and Development Update - Turn is advancing its phase 2 trial of GX-03 for moderate to severe eczema, with approximately 25% of the targeted sample size having completed the trial and ongoing enrollment [4] - The study of GX-03, the first topical IL-36/IL-31 inhibitor, is on track, with topline results expected in 2026 and no safety concerns reported for the 25% of participants who have completed the trial [5] - The company is also progressing its thermostable intranasal vaccine initiative, with in-vivo studies set to begin in Q4 2025, reflecting its commitment to global health [6] Company Overview - Turn Therapeutics focuses on developing and commercializing products for dermatology, wound care, and infectious diseases, having received three FDA clearances for its proprietary formulations and advancing late-stage clinical programs [8]

Core Insights - Turn Therapeutics has launched a comprehensive communications initiative aimed at enhancing engagement with shareholders and the healthcare community, which includes a recurring webinar series and a Founder Blog by CEO Bradley Burnam [1][2]. Company Overview - Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases. The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [3]. Communications Initiative - The initiative includes a webinar series that will cover ongoing programs, strategic milestones, and upcoming developments, with the first session scheduled for October 22, 2025, at 2:00 PM ET [2][3]. - The Founder Blog will provide updates on company progress, research insights, and perspectives on growth and innovation, with further details to be announced [2]. Commitment to Public Health - Turn Therapeutics is also pursuing global health initiatives, particularly in thermostable vaccine delivery, aimed at serving underserved areas worldwide, reflecting the company's commitment to public health innovation [3].

Core Insights - Turn Therapeutics has appointed Dr. Kent E. Kester to its Board of Directors, enhancing its leadership in clinical and scientific domains at a crucial growth phase [1][3] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases [1][7] - The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [7] Leadership Experience - Dr. Kester is a globally recognized infectious disease physician with over two decades of leadership experience in government, industry, and academia [2][4] - He has held senior roles, including Commander of the Walter Reed Army Institute of Research, and has led multi-center clinical programs from Phase 1 through pivotal studies [2][5] Strategic Importance - The appointment of Dr. Kester is expected to strengthen governance, sharpen strategy, and ensure a focus on patient impact and long-term value creation for Turn Therapeutics [3] - Dr. Kester's expertise in drug development and infectious disease is seen as invaluable for advancing the company's late-stage programs and approaching key regulatory milestones [3] Commitment to Public Health - Turn Therapeutics is pursuing global health initiatives, including thermostable vaccine delivery aimed at underserved areas, reflecting its commitment to public health innovation [7]